JP2012523434A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012523434A5 JP2012523434A5 JP2012504907A JP2012504907A JP2012523434A5 JP 2012523434 A5 JP2012523434 A5 JP 2012523434A5 JP 2012504907 A JP2012504907 A JP 2012504907A JP 2012504907 A JP2012504907 A JP 2012504907A JP 2012523434 A5 JP2012523434 A5 JP 2012523434A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- amylin agonist
- agonist compound
- composition according
- month
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 claims 13
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 claims 13
- 239000000556 agonist Substances 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 13
- 241000124008 Mammalia Species 0.000 claims 4
- 230000009245 menopause Effects 0.000 claims 4
- 208000008589 Obesity Diseases 0.000 claims 3
- 206010033307 Overweight Diseases 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- 101150035467 BDNF gene Proteins 0.000 claims 2
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 claims 2
- 210000000577 adipose tissue Anatomy 0.000 claims 2
- 150000001413 amino acids Chemical group 0.000 claims 2
- 230000002950 deficient Effects 0.000 claims 2
- 229940011871 estrogen Drugs 0.000 claims 2
- 239000000262 estrogen Substances 0.000 claims 2
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 claims 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims 2
- 238000009806 oophorectomy Methods 0.000 claims 2
- 230000004584 weight gain Effects 0.000 claims 2
- 235000019786 weight gain Nutrition 0.000 claims 2
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- 108010011459 Exenatide Proteins 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- 101800004266 Glucagon-like peptide 1(7-37) Proteins 0.000 claims 1
- 108010092277 Leptin Proteins 0.000 claims 1
- 102000016267 Leptin Human genes 0.000 claims 1
- 206010030247 Oestrogen deficiency Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 108091005466 amylin receptors Proteins 0.000 claims 1
- 235000019789 appetite Nutrition 0.000 claims 1
- 230000036528 appetite Effects 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 229960001519 exenatide Drugs 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 230000030136 gastric emptying Effects 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 229940039781 leptin Drugs 0.000 claims 1
- 108700008455 metreleptin Proteins 0.000 claims 1
- 229960000668 metreleptin Drugs 0.000 claims 1
- OKPYIWASQZGASP-UHFFFAOYSA-N n-(2-hydroxypropyl)-2-methylprop-2-enamide Chemical compound CC(O)CNC(=O)C(C)=C OKPYIWASQZGASP-UHFFFAOYSA-N 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical group C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 238000001525 receptor binding assay Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000036186 satiety Effects 0.000 claims 1
- 235000019627 satiety Nutrition 0.000 claims 1
- 210000002027 skeletal muscle Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16831709P | 2009-04-10 | 2009-04-10 | |
| US61/168,317 | 2009-04-10 | ||
| PCT/US2010/030625 WO2010118384A2 (en) | 2009-04-10 | 2010-04-09 | Amylin agonist compounds for estrogen-deficient mammals |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012523434A JP2012523434A (ja) | 2012-10-04 |
| JP2012523434A5 true JP2012523434A5 (enExample) | 2013-05-30 |
Family
ID=42936899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012504907A Pending JP2012523434A (ja) | 2009-04-10 | 2010-04-09 | エストロゲン欠乏哺乳類のためのアミリンアゴニスト化合物 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20120071401A1 (enExample) |
| EP (1) | EP2416797A4 (enExample) |
| JP (1) | JP2012523434A (enExample) |
| WO (1) | WO2010118384A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011063414A1 (en) * | 2009-11-23 | 2011-05-26 | Amylin Pharmaceuticals, Inc. | Polypeptide conjugate |
| CA2868688A1 (en) | 2012-04-03 | 2013-10-10 | Trustees Of Boston University | Compositions, methods and assays comprising amylin or amlyin analogs for abeta-peptide mediated disorders |
| WO2020180534A1 (en) | 2019-03-01 | 2020-09-10 | President And Fellows Of Harvard College | Methods and compositions for protein delivery |
| TWI850611B (zh) | 2020-12-18 | 2024-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | Glp-1及澱粉素受體之共促效劑 |
| MX2024005705A (es) | 2021-11-10 | 2024-05-24 | I2O Therapeutics Inc | Composiciones de liquidos ionicos. |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4572208A (en) | 1983-06-29 | 1986-02-25 | Utah Medical Products, Inc. | Metabolic gas monitoring apparatus and method |
| FI78231C (fi) | 1984-11-21 | 1989-07-10 | Instrumentarium Oy | Maetanordning foer metaboliska storheter anslutbar till en respirator. |
| US5405831A (en) * | 1989-07-08 | 1995-04-11 | Amylin Pharmaceuticals, Inc. | Treatment of bone disorders |
| WO1992015317A1 (en) | 1991-03-08 | 1992-09-17 | Amylin Pharmaceuticals, Inc. | Synthetic preparation of amylin and amylin analogues |
| HU222249B1 (hu) | 1991-03-08 | 2003-05-28 | Amylin Pharmaceuticals Inc. | Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására |
| US6071695A (en) * | 1992-02-21 | 2000-06-06 | Creative Biomolecules, Inc. | Methods and products for identification of modulators of osteogenic protein-1 gene expression |
| US5854391A (en) | 1993-03-18 | 1998-12-29 | The Scripps Research Institute | Glycosylation of peptides using glycosyl phosphite reagents |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| US5827734A (en) | 1995-01-20 | 1998-10-27 | University Of Washington | Materials and methods for determining ob protein in a biological sample |
| US5532336A (en) | 1995-01-31 | 1996-07-02 | Eli Lilly And Company | Anti-obesity proteins |
| US5569744A (en) | 1995-01-31 | 1996-10-29 | Eli Lilly And Company | Anti-obesity proteins |
| US5567678A (en) | 1995-01-31 | 1996-10-22 | Eli Lilly And Company | Anti-obesity proteins |
| US5563243A (en) | 1995-01-31 | 1996-10-08 | Eli Lilly And Company | Anti-obesity proteins |
| US5569743A (en) | 1995-01-31 | 1996-10-29 | Eli Lilly And Company | Anti-obesity proteins |
| US5580954A (en) | 1995-01-31 | 1996-12-03 | Eli Lilly And Company | Anti-obesity proteins |
| US5605886A (en) | 1995-01-31 | 1997-02-25 | Eli Lilly And Company | Anti-obesity proteins |
| US5567803A (en) | 1995-01-31 | 1996-10-22 | Eli Lilly And Company | Anti-obesity proteins |
| US5552524A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| US5594104A (en) | 1995-01-31 | 1997-01-14 | Eli Lilly And Company | Anti-obesity proteins |
| US5525705A (en) | 1995-01-31 | 1996-06-11 | Eli Lilly And Company | Anti-obesity proteins |
| US5563244A (en) | 1995-01-31 | 1996-10-08 | Eli Lilly And Company | Anti-obesity proteins |
| US5552523A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| US5559208A (en) | 1995-01-31 | 1996-09-24 | Eli Lilly And Company | Anti-obesity proteins |
| AU4766096A (en) | 1995-01-31 | 1996-08-21 | Eli Lilly And Company | Anti-obesity proteins |
| US5691309A (en) | 1995-01-31 | 1997-11-25 | Eli Lilly And Company | Anti-obesity proteins |
| US5563245A (en) | 1995-01-31 | 1996-10-08 | Eli Lilly And Company | Anti-obesity proteins |
| US5521283A (en) | 1995-01-31 | 1996-05-28 | Eli Lilly And Company | Anti-obesity proteins |
| US5574133A (en) | 1995-01-31 | 1996-11-12 | Eli Lilly And Company | Anti-obesity proteins |
| US5552522A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| US5554727A (en) | 1995-01-31 | 1996-09-10 | Eli Lilly And Company | Anti-obesity proteins |
| EP0725078A1 (en) | 1995-01-31 | 1996-08-07 | Eli Lilly And Company | Anti-obesity proteins |
| US5594101A (en) | 1995-03-03 | 1997-01-14 | Eli Lilly And Company | Anti-obesity proteins |
| US5719266A (en) | 1995-03-17 | 1998-02-17 | Eli Lilly And Company | Anti-obesity proteins |
| EP0736599A3 (en) | 1995-04-03 | 1996-12-11 | Takeda Chemical Industries Ltd | The rat obesity gene, its gene product and its production |
| US5614379A (en) | 1995-04-26 | 1997-03-25 | Eli Lilly And Company | Process for preparing anti-obesity protein |
| GB9509164D0 (en) | 1995-05-05 | 1995-06-28 | Smithkline Beecham Plc | Novel compounds |
| DE741187T1 (de) | 1995-05-05 | 1997-04-30 | Hoffmann La Roche | Rekombinante Obesitäts-(OB)-Proteine |
| AU5737696A (en) | 1995-05-08 | 1996-11-29 | Chiron Corporation | Nucleic acids for treating obesity |
| WO1996037517A1 (en) | 1995-05-26 | 1996-11-28 | Eli Lilly And Company | Rhesus ob protein and dna |
| US5739106A (en) * | 1995-06-07 | 1998-04-14 | Rink; Timothy J. | Appetite regulating compositions |
| AU6284896A (en) | 1995-06-22 | 1997-01-22 | Eli Lilly And Company | Obesity protein intermediates and their preparation and use |
| CZ416797A3 (cs) | 1995-06-30 | 1998-06-17 | Eli Lilly And Company | Použití leptinu nebo leptonových mimetik pro výrobu léčiv pro léčení nebo prevenci diabetes mellitus a kompozice s jeho obsahem |
| WO1997016550A1 (en) | 1995-11-02 | 1997-05-09 | Bristol-Myers Squibb Company | Polypeptide fragments derived from the obese gene product |
| AU1406497A (en) | 1995-12-06 | 1997-06-27 | Schering Corporation | Mutational variants of mammalian ob gene proteins |
| US6013009A (en) | 1996-03-12 | 2000-01-11 | Karkanen; Kip Michael | Walking/running heart rate monitoring system |
| EP0912609A2 (en) | 1996-06-06 | 1999-05-06 | Smithkline Beecham Plc | Fragments of leptin (ob protein) |
| AU735178B2 (en) | 1996-09-20 | 2001-07-05 | Hoechst Aktiengesellschaft | Use of leptin antagonists for treating insulin resistance in type II diabetes |
| AU4582597A (en) | 1996-10-11 | 1998-05-11 | Eli Lilly And Company | Therapeutic proteins |
| US6410511B2 (en) | 1997-01-08 | 2002-06-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| US6309360B1 (en) | 1997-03-17 | 2001-10-30 | James R. Mault | Respiratory calorimeter |
| KR20010013414A (ko) | 1997-06-06 | 2001-02-26 | 피터 기딩스 | 당뇨병의 치료를 위한 렙틴 길항제의 용도 |
| US7910548B2 (en) | 1997-06-06 | 2011-03-22 | Amylin Pharmaceuticals, Inc. | Methods for treating obesity |
| WO1999045026A1 (en) | 1998-03-05 | 1999-09-10 | Chiron Corporation | Method for increasing the serum half-life of a biologically active molecule |
| WO1999063614A1 (en) | 1998-05-29 | 1999-12-09 | Catalysts & Chemicals Industries Co., Ltd. | Method of manufacturing photoelectric cell and oxide semiconductor for photoelectric cell |
| US6924264B1 (en) | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
| CA2363712C (en) | 1999-05-17 | 2011-05-10 | Conjuchem Inc. | Long lasting insulinotropic peptides |
| TW514510B (en) | 1999-06-11 | 2002-12-21 | Tanita Seisakusho Kk | Method and apparatus for measuring distribution of body fat |
| US6468222B1 (en) | 1999-08-02 | 2002-10-22 | Healthetech, Inc. | Metabolic calorimeter employing respiratory gas analysis |
| TW515705B (en) | 2000-05-31 | 2003-01-01 | Yamato Scale Co Ltd | Visceral fat meter |
| US6475158B1 (en) | 2000-10-24 | 2002-11-05 | Korr Medical Technologies, Inc. | Calorimetry systems and methods |
| EP1354888B1 (en) * | 2000-12-28 | 2009-05-20 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxypyrazole derivatives and use thereof in medicines |
| AU2003290563A1 (en) | 2002-10-31 | 2004-05-25 | Clf Medical Technology Acceleration Program, Inc. | Leptin-related peptides |
| JP2008500281A (ja) | 2004-02-11 | 2008-01-10 | アミリン・ファーマシューティカルズ，インコーポレイテッド | アミリンファミリーペプチドおよびそれらを作成し使用するための方法 |
| KR101427024B1 (ko) | 2004-02-11 | 2014-08-05 | 아스트라제네카 파마수티컬스 엘피 | 선택가능한 특성을 갖는 하이브리드 폴리펩티드 |
| US7399744B2 (en) * | 2004-03-04 | 2008-07-15 | Amylin Pharmaceuticals, Inc. | Methods for affecting body composition |
| CN101094689B (zh) * | 2004-11-01 | 2013-06-12 | 安米林药品有限责任公司 | 治疗肥胖以及肥胖相关疾病和病症的方法 |
| US8394765B2 (en) * | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
| US20090286723A1 (en) | 2005-02-11 | 2009-11-19 | Amylin Pharmaceuticals, Inc. | Hybrid Polypeptides with Selectable Properties |
| BRPI0609595A8 (pt) * | 2005-03-31 | 2018-05-15 | Amylin Pharmaceuticals Inc | composições e métodos para o controle, prevenção e tratamento da obesidade e desordens alimentares |
| KR101399178B1 (ko) * | 2005-08-11 | 2014-06-18 | 아스트라제네카 파마수티컬스 엘피 | 선별가능한 특성을 갖는 하이브리드 폴리펩티드 |
| WO2007053946A1 (en) | 2005-11-09 | 2007-05-18 | Conjuchem Biotechnologies Inc. | Method of treating diabetes and/or obesity with reduced nausea side effects using an insulinotropic peptide conjugated to albumin |
| JP5252435B2 (ja) * | 2006-03-15 | 2013-07-31 | ノボ・ノルデイスク・エー／エス | アミリン誘導体 |
| US20070287684A1 (en) * | 2006-05-22 | 2007-12-13 | Irshad Chaudry | Methods and compositions for treating trauma-hemorrhage using estrogen and derivatives thereof |
| CN101125207B (zh) | 2006-11-14 | 2012-09-05 | 上海华谊生物技术有限公司 | 带有聚乙二醇基团的艾塞丁或其类似物及其制剂和用途 |
| JP2008169195A (ja) | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
| KR101638035B1 (ko) * | 2007-01-22 | 2016-07-11 | 지티엑스, 인코포레이티드 | 핵 수용체에 결합하는 물질 |
| US8268806B2 (en) * | 2007-08-10 | 2012-09-18 | Endorecherche, Inc. | Pharmaceutical compositions |
-
2010
- 2010-04-09 WO PCT/US2010/030625 patent/WO2010118384A2/en not_active Ceased
- 2010-04-09 EP EP20100762535 patent/EP2416797A4/en not_active Withdrawn
- 2010-04-09 JP JP2012504907A patent/JP2012523434A/ja active Pending
- 2010-04-09 US US13/263,070 patent/US20120071401A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6059802B2 (ja) | 長時間作用型ｇｌｐ−１ペプチドの使用 | |
| JP5969461B2 (ja) | Ｇｌｐ−１受容体作動薬とガストリンとのペプチド複合体及びその使用 | |
| JP2012523434A5 (enExample) | ||
| Verspohl | Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors | |
| JP2019510739A5 (enExample) | ||
| EP1581248B1 (en) | Modification of feeding behaviour and weight control by oxyntomodulin | |
| JP2020007338A (ja) | グルカゴン及びｇｌｐ−１共アゴニスト化合物 | |
| JP2017505284A5 (enExample) | ||
| IL317065A (en) | Chimeric inducible cytokine receptors | |
| CN1551780A (zh) | 用于预防或治疗体重过重的胃肠激素 | |
| CN118265720A (zh) | 用于治疗代谢病症和肝病的组合物和方法 | |
| JP6366575B2 (ja) | 二重アシル化されたｇｌｐ−１誘導体 | |
| CN104144704B (zh) | Glp‑1受体激动剂肽胃泌素缀合物 | |
| Alexiadou et al. | Gastrointestinal peptides as therapeutic targets to mitigate obesity and metabolic syndrome | |
| JP2016512213A5 (enExample) | ||
| Akarte et al. | A novel long acting DPP-IV inhibitor PKF-275-055 stimulates β-cell proliferation resulting in improved glucose homeostasis in diabetic rats | |
| JP2015502918A5 (enExample) | ||
| CN119894527A (zh) | 用于治疗代谢和肝脏病症的药物制剂和方法 | |
| Reid et al. | Efpeglenatide. Glucagon-like peptide 1 (GLP-1) receptor agonist, treatment for type 2 diabetes | |
| Franek et al. | The role of glucagon-like peptide 1 in glucose homeostasis and in other aspects of human physiology | |
| JP2008539723A (ja) | 下垂体アデニル酸シクラーゼ活性化ペプチド（ｐａｃａｐ）受容体（ｖｐａｃ２）アゴニストおよびそれらの薬理学的使用方法 | |
| RU2016119121A (ru) | Селективные соединения пептида yy и их применения | |
| WO2009080608A1 (en) | Y2 receptor agonists | |
| WO2015197098A1 (en) | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases | |
| RU2025118079A (ru) | Аналог инкретина и его применение |